'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer

被引：6
|
作者：
Voskoboynik, Mark [1 ,2 ]
Staffurth, John [3 ]
Malik, Zafar [4 ]
Sweeney, Christopher [5 ,6 ]
Chowdhury, Simon [1 ,2 ]
机构：
[1] Guys Hosp, Dept Med Oncol, London SE1 9RT, England
[2] Sarah Cannon Res Inst UK, London, England
[3] Cardiff Univ, Inst Canc & Genet, Velindre Canc Ctr, Cardiff, S Glam, Wales
[4] Clatterbridge Canc Ctr, Bebington, Wirral, England
[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2014年 / 14卷 / 11期
关键词：
CHAARTED; docetaxel; hormone sensitive; metastatic prostate cancer; Sweeney; MITOXANTRONE PLUS PREDNISONE; INCREASED SURVIVAL; OPEN-LABEL; CHEMOTHERAPY; ABIRATERONE; ENZALUTAMIDE; PHASE-3; TRIAL;
D O I：
10.1586/14737140.2014.971112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Docetaxel has an established role in the treatment of metastatic castrate-resistant prostate cancer. A number of recent treatments have been shown to improve the survival outcomes for this group of patients and many with improved toxicity profiles, bringing the role of docetaxel into question. We discuss the results and implications of the CHAARTED study that demonstrated a significant improvement in overall survival with docetaxel in metastatic hormone-sensitive prostate cancer. © Informa UK, Ltd.
引用
收藏
页码：1253 / 1256
页数：4
相关论文
共 50 条
  • [1] Docetaxel for hormone-sensitive metastatic prostate cancer
    Baker, Holly
    LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
  • [2] Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    Kartolo, Adi
    Tannock, Ian F.
    Badillo, Francisco E. Vera
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3573 - +
  • [3] Docetaxel Improves Survival in Metastatic Hormone-Sensitive Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 549 - 549
  • [4] Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer?
    Liaw, Bobby C.
    Oh, William K.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (09) : 17 - 20
  • [5] Metastatic hormone-sensitive prostate cancer
    Gravis, Gwenaelle
    Salem, Naji
    Walz, Jochen
    BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
  • [6] Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
    de Groot, Ietsen
    Brinkman, Ithamar
    Luijendijk-de Bruin, Daphne
    Poort, Sharon
    van Rooijen, Johan M.
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 33 : 48 - 55
  • [7] Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
    Lendorf, Maria Elisabeth
    Petersen, Peter Meidahl
    Svendsen, Andrea Steen
    Lindberg, Henriette
    Brasso, Klaus
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 24 : 25 - 33
  • [8] Management of Metastatic Hormone-Sensitive Prostate Cancer
    Bernard, Brandon
    Sweeney, Christopher J.
    CURRENT UROLOGY REPORTS, 2015, 16 (03)
  • [9] Rezvilutamide for metastatic hormone-sensitive prostate cancer
    Singh, Kirti
    Mandal, Swarnendu
    Nayak, Prasant
    Das, Manoj
    Tripathy, Sambit
    LANCET ONCOLOGY, 2022, 23 (11): : E490 - E490
  • [10] Treatment of metastatic hormone-sensitive prostate cancer
    Rane, Jayant K.
    Chowdhury, Amani
    Kinnaird, William
    Marks, Gillian
    Davda, Reena
    TRENDS IN UROLOGY & MENS HEALTH, 2021, 12 (06) : 7 - 10
12345